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— a guide for clinicians
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The aim of this article is to present briefly new pathological entities which are recently increasingly commonly used 
in pathology reports, as well as to discuss their clinical consequences. The new WHO classification of breast diseases 
includes, inter alia, invasive carcinoma of no special type: this is not a specific entity, but rather a group of malignan-
cies without specific features. The lobular hyperplasia group includes a classical variant and a pleomorphic variant 
of lobular carcinoma in situ, as well as atypical lobular hyperplasia. The ductal hyperplasia group, according to the 
current revision of the WHO classification of breast diseases, encompasses: typical (i.e. non-atypical) ductal hyperplasia, 
columnar cell change, columnar cell hyperplasia, atypical ductal hyperplasia. The mesenchymal breast hyperplasia 
group includes pseudoangiomatous stromal hyperplasia. We briefly discuss the above mentioned entities together 
with their respective clinical and therapeutic consequences.
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Introduction 
A pathomorphologist is obliged to comply, in histo-
pathological reports, with the terminology applied in the 
current edition of the breast cancer classification published 
regularly under the auspices of the World Health Organi-
sation (WHO), which was last updated in 2012 [1]. For the 
purpose of effective collaboration with other specialists, it is 
necessary to make the terminology completely understan-
dable and clear for all medical specialists involved in the 
treatment of breast cancer. It is worthwhile in this context 
to quote the title of an excellent book written by Juan Rosai 
discussing the history of pathomorphology in the USA — 
“Guiding the Surgeon’s Hand”. The pathomorphologist, in 
order to be able to influence decisions taken by a surgeon, 
must use the current terminology in their reports and, at 
the same time, make sure that clinicians correctly interpret 
this terminology.
The objective of this paper is to present selected new 
disease entities and terms which have recently appeared in 
pathological reports, as well as to discuss the consequences 
of these new entities and terms for patients.
Infiltrating carcinoma NST
In the current WHO classification the name of the most 
common histological type of infiltrating breast carcinoma 
has been changed. It has been recognised that the term 
which had been used so far, i.e. infiltrating ductal carcinoma 
is not correct, as it suggests the origin of cancer cells solely 
from the epithelium lining the ducts of the breast gland, as 
opposed to the cells of lobular breast cancer (which in turn 
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Table I. pCR rate within the lymph nodes after preoperative chemotherapy
Study N The rate of pCR in the 
lymph nodes 
ACOSOG Z1071 (cT0–4N1/2)
16 649 41%
SN FNAC (cT0–3N1/2)
17 145 35%
Mamtani (cT0–3N1/2)
18 195 49%
were supposed to originate from the epithelium within the 
glandular lobules). In current pathology, there is no evidence 
for the above statements. Furthermore, it is known that 
the above term does not define a morphological entity, 
but rather a group of diverse cancers, which, however, lack 
any distinctive features (as in the case of e.g. tubular can-
cer), which would allow for distinguishing a special entity 
among them — therefore this group was called infiltrating 
carcinoma of no special type (NST). Thus this is not a new 
histological type of breast cancer, but a synonym for a pre-
viously used term: ductal infiltrating cancer not otherwise 
specified (NOS). The current WHO classification allows for 
the use of alternative terms for the same disease, such as 
ductal carcinoma NST, ductal carcinoma NOS, infiltrating 
ductal carcinoma, though the use of these terms is not 
recommended [1].
Lobular hyperplasia 
In the group of lobular hyperplasia, the new classifi-
cation distinguishes the following morphological entities: 
classical and pleomorphic lobular carcinoma in situ and 
atypical lobular hyperplasia. Thus, the group contains all 
kinds of atypical hyperplasias of glandular epithelium within 
the terminal duct lobular unit (TDLU) [1].
Atypical lobular hyperplasia (ALH) and lobular carci-
noma in situ (LCIS) are not completely separate morpho-
logical entities. Atypical lobular hyperplasia and LCIS are 
rather a continuum of the same lesions, i.e. a hyperplasia 
of small, monotonous and incohesive epithelial cells within 
terminal ductal-lobular units (TDLU). The only criterion that 
distinguishes between ALH and LCIS is the extent of the 
lobule involvement: if the hyperplasia occupies < 50% lo-
bule, then a pathomorphologist diagnoses ALH, whilst if the 
hyperplasia occupies > 50% lobule, then LCIS is diagnosed. 
Both diagnoses are breast cancer risk factors, constituting 
so-called non-obligatory precursors of infiltrating carcino-
mas, both lobular and NST. What is more, the risk concerns 
both breasts and not only the one in which the atypical 
lobular hyperplasia was found. In the case of ALH, the risk 
of occurrence of infiltrating carcinoma is 4–5 times larger, 
whilst in the case of LCIS — 8–12 times larger than in the 
population of women in whose case lobular hyperplasia has 
never been diagnosed. 
It must be stressed that in the case of a diagnosis of 
ALH and the classical form of LCIS, the WHO classification 
does not require a pathologist to define the condition and 
width of surgical margins. Yet in the case where, in accor-
dance with the WHO classification, a pathomorphologist 
diagnoses one of the variations of LCIS (i.e. pleomorphic 
LCIS or comedonecrotic LCIS), then, if the lesion was found 
in a core-needle biopsy, it is necessary to remove the entire 
cancer focus. This is because the above LCIS variants are 
accompanied by micro-infiltration or infiltration, and the 
associated clinical activity should be more aggressive than 
in the case of classical LCIS [2].
Ductal hyperplasia 
In the group of ductal hyperplasia, the WHO classifica-
tion distinguishes, inter alia, usual (i.e. not atypical) ductal 
hyperplasia (UDH), various columnar cell changes or co-
lumnar cell hyperplasia or flat epithelial atypia, (FEA) and 
atypical ductal hyperplasia (ADH) [1].
Within the terminal end of a ductal-lobular unit, there 
might develop some morphological lesions made up from 
columnar cells — increased, frequently dilated glandular 
lobules and terminal ductules lined with epithelial columnar 
cells, yet without any features of nuclear atypia. In accor-
dance with the definition, if only 1 layer of columnar cells 
is found, then a columnar cell change is diagnosed, whilst if 
more than 1 layer of columnar cells is found, then columnar 
cell hyperplasia must be diagnosed. Such lesions frequently 
accompany benign lesions in the breasts (such as cysts and 
UDH) and lobular hyperplasias; they are accompanied by 
microcalcifications. Moreover, the described lesions frequ-
ently co-exist with LCIS/ALH and tubular breast cancer [3]. 
Columnar cells lesions and hyperplasias increase the risk of 
breast cancer development only to a slight degree (about 
1.5 times). 
The cells of a columnar cell lesion may have some slight 
cytological atypia. Then a pathomorphologist diagnoses flat 
epithelial atypia (FEA). In the microscopic image there are 
one or more layers of cells which do not make up atypical 
structures, but are characterised by a typical nuclear atypia 
(of low grade type). The synonym which WHO allows here is 
columnar cell hyperplasia/change with atypia (FEA).
There is a strong correlation between FEA and the pre-
sence of lobular hyperplasia (LCIS/ALH), atypical ductal hy-
perplasia (ADH), low grade DCIS [3] and low grade infiltrating 
cancers. The risk of their development into infiltrating carci-
noma is small (smaller than in the case of ALH and ADH). In 
the case of an FEA diagnosis in core needle biopsy material, 
in accordance with the recommendations listed in the WHO 
classification, the clinical course is not definitively determi-
ned and depends, inter alia, upon the level of correlation of 
radiological and pathological evaluation, whilst the surgical 
recommendations are more precise: it is recommended 
either to place the patient under strict clinical observation 
or qualify them for a complete resection of the focus [2].
Atypical ductal hyperplasia (ADH), in accordance with 
the WHO classification, means a hyperplasia of monomor-
phic epithelial cells within a terminal duct lobular unit. The 
microscopic picture reveals both a cytological atypia and 
a disorder (in other words — atypia) of a structural type 
(usually distinctly marked). The main criterion distinguishing 
between ADH and low grade DCIS is the extent of the le-
sion: the involvement of > 2 neighbouring ducts or a size 
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of r > 2 mm allows a diagnosis of low grade DCIS. Unfortu-
nately, the evaluation of this criterion leads to some doubt 
in cases where the specimen comes from a core needle 
biopsy. The risk of breast cancer involvement in the case 
of ADH is 3–5 times larger than in the general population. 
This is why, the treatment should consist — in the case of 
a core needle biopsy diagnosis of ADH — of the removal of 
the lesion. If, however, the presence of ADH is found in the 
resection margin after the cancer removal, then there are 
no grounds for surgical radicalisation. In accordance with 
the recommendation of the National Comprehensive Can-
cer Network (NCCN), the presence of ADH in the resection 
margin of another, benign breast lesion may (but does not 
have to) lead to a surgical radicalisation [4]. In the case of 
such a lesion, it is also recommended to administer chemo-
-prevention, yet in practice, this is rarely used [5].
Mesenchymal stromal hyperplasia 
In this group of lesions, the current WHO classification [1] 
lists pseudoangiomatous stromal hyperplasia (PASH), which 
is defined as a benign hyperplasia of myofibroblasts in the 
glandular stroma, taking the morphological form of slit-like 
(pseudovascular) spaces lined with spindle cells (Fig.  1). 
A characteristic property of PASH is a correlation with hor-
monal imbalance (e.g. before menopause or in the period 
of puberty in men), the use of hormonal contraception or 
HRT. The radiological image does not reveal any microcalci-
fications, but PASH may form a clinically visible tumour. The 
treatment is not definitively specified, but the lesion may be 
closely watched after verification with a core needle biopsy, 
if there is no clinical doubt or clinical symptoms. Otherwise 
tumour resection should be considered [6, 7]. 
Conclusions 
The terminology used in pathomorphological reports 
should be unambiguous and understandable for clinicians 
who, on the basis of that report, take decisions concerning 
the treatment options (or the abandonment of active treat-
ment). The objective of this short paper was to present the 
typical abbreviations (such as ALD, UDH, FEA, ADH, PASH) 
which are frequently quoted in current national pathological 
reports describing tissue specimens as well as the clinical 
significance of the lesions described in such reports. 
Conflict of interest: none declared
Joanna B. Wysocka, MD
Department of Tumour Pathology
Maria Skłodowska-Curie Memorial Cancer Centre 
and Institute of Oncology
Kraków Branch
Garncarska St. 11
31–115 Kraków, Poland
e-mail: jwysocka@mp.pl
Received: 4 Jun 2017 
Accepted: 9 Jun 2017
The paper was written on the basis of a lecture delivered 
by the first author of the text during the 5th Winter Oncolo-
gical Forum organised by the Polish Society of Oncological 
Surgery in Zakopane in January 2017. 
Figure 1. Pseudoangiomatous stromal hyperplasia (PASH) the cells lining the spaces here are characterised by the presence of small nuclei without 
any properties of atypia. No mitotic division figures are observed. HE staining, 200 × magnification
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